Summary
238.69 -2.74(-1.13%)07/01/2024
Align Technology, Inc. (ALGN)
Align Technology, Inc. (ALGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.13 | -0.31 | -4.82 | -26.42 | -12.79 | -30.08 | -11.84 | 1,329.87 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 238.69 | |
| Open | 241.65 | |
| High | 247.35 | |
| Low | 238.69 | |
| Volume | 438,324 | |
| Change | -2.74 | |
| Change % | -1.13 | |
| Avg Volume (20 Days) | 702,781 | |
| Volume/Avg Volume (20 Days) Ratio | 0.62 | |
| 52 Week Range | 176.34 - 413.20 | |
| Price vs 52 Week High | -42.23% | |
| Price vs 52 Week Low | 35.36% | |
| Range | -1.08 | |
| Gap Up/Down | -0.86 | |
Fundamentals | ||
| Market Capitalization (Mln) | 18,175 | |
| EBIDTA | 816,784,000 | |
| PE Ratio | 44.8350 | |
| PEG Ratio | 1.9618 | |
| WallStreet Target Price | 338.96 | |
| Book Value | 49.9440 | |
| Earnings Per Share | 6.0600 | |
| EPS Estimate Current Quarter | 1.9700 | |
| EPS Estimate Next Quarter | 2.3800 | |
| EPS Estimate Current Year | 9.6500 | |
| EPS Estimate Next Year | 10.9800 | |
| Diluted EPS (TTM) | 6.0600 | |
| Revenues | ||
| Profit Marging | 0.1180 | |
| Operating Marging (TTM) | 0.1545 | |
| Return on asset (TTM) | 0.0702 | |
| Return on equity (TTM) | 0.1277 | |
| Revenue TTM | 3,916,544,000 | |
| Revenue per share TTM | 51.5410 | |
| Quarterly Revenue Growth (YOY) | 0.0580 | |
| Quarterly Earnings Growth (YOY) | 0.2190 | |
| Gross Profit (TTM) | 2,636,675,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 44.8350 | |
| Forward PE | 36.4964 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.5278 | |
| Revenue Enterprise Value | 5.9170 | |
| EBITDA Enterprise Value | 28.6002 | |
| Shares | ||
| Shares Outstanding | 75,281,696 | |
| Shares Float | 70,215,229 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 6.53 | |
| Institutions (%) | 89.27 | |
06/28 13:08 EST - invezz.com
Hedgeye adds Align Technology stock to its list of short ideas
Align Technology Inc (NASDAQ: ALGN) is keeping in the green at writing even after Hedgeye named it a new short idea on Friday. Shares of the 3D digital scanners company are down more than 20% versus their year-to-date high.
Hedgeye adds Align Technology stock to its list of short ideas
Align Technology Inc (NASDAQ: ALGN) is keeping in the green at writing even after Hedgeye named it a new short idea on Friday. Shares of the 3D digital scanners company are down more than 20% versus their year-to-date high.
06/25 06:15 EST - investorplace.com
You've Been Warned! 3 3D Printing Stocks to Buy Now or Regret Forever.
You've come to the right place if you're looking for secular growth stocks. This article explores 3D printing stocks, poised to benefit from an annualized industry growth rate of 23.5% until 2030.
You've Been Warned! 3 3D Printing Stocks to Buy Now or Regret Forever.
You've come to the right place if you're looking for secular growth stocks. This article explores 3D printing stocks, poised to benefit from an annualized industry growth rate of 23.5% until 2030.
06/14 08:41 EST - zacks.com
4 Stocks to Buy Amid Dental Supplies Industry Challenges
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
06/12 09:20 EST - zacks.com
Buy These 5 Stocks on the Dip to Gain From Wall Street Rally
Five top stocks at attractive valuations are: DELL, OKTA, GPN, ALGN, RBLX.
Buy These 5 Stocks on the Dip to Gain From Wall Street Rally
Five top stocks at attractive valuations are: DELL, OKTA, GPN, ALGN, RBLX.
06/10 11:00 EST - zacks.com
Align Technology (ALGN) Gains From New Alliances, Global Growth
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
Align Technology (ALGN) Gains From New Alliances, Global Growth
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
06/03 08:30 EST - businesswire.com
Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company's fourteenth Annual Research Award Program. “Align is delighted to announce the awards for research that l.
Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company's fourteenth Annual Research Award Program. “Align is delighted to announce the awards for research that l.
05/24 12:39 EST - zacks.com
Why Is Align Technology (ALGN) Down 18.7% Since Last Earnings Report?
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock?
Why Is Align Technology (ALGN) Down 18.7% Since Last Earnings Report?
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock?
05/22 17:00 EST - businesswire.com
Align Technology Appoints Emory Wright, EVP Direct Fabrication Manufacturing Platform to Build the Company's Next Generation Manufacturing Operations -- Wright Plans to Retire in 2026
TEMPE, Ariz. & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced it has appointed Emory Wright, executive vice president, direct fabrication manufacturing platform, effective immediately. Mr. Wright will transition his current resp.
Align Technology Appoints Emory Wright, EVP Direct Fabrication Manufacturing Platform to Build the Company's Next Generation Manufacturing Operations -- Wright Plans to Retire in 2026
TEMPE, Ariz. & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced it has appointed Emory Wright, executive vice president, direct fabrication manufacturing platform, effective immediately. Mr. Wright will transition his current resp.
05/20 00:00 EST - https://www.zacks.com
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Surmodics, Inc. (SRDX Quick QuoteSRDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter performance and consistent efforts to boost research and development (R&D) are expected to contribute further. Yet, concerns regarding regulatory headwinds and reliance on third parties persist.So far this year, this current Zacks Rank #3 (Hold) company has declined 4.8% against the industry’s 4.2% rise and the S&P 500’s 11.6% growth.The renowned medical device and in-vitro diagnostics technology provider has a market capitalization of $493.68 million. Surmodics projects 97.2% growth for fiscal 2025 and expects to maintain its strong performance. SRDX’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average earnings surprise being 165.93%. Image Source: Zacks Investment ResearchLet’s delve deeper.Consistent Efforts to Boost R&D: Surmodics’ solid efforts to improve its R&D stature have been a key growth driver, which raises our optimism. The company’s pipeline of vascular intervention medical device products under development and recently commercialized include primary platforms like DCBs, Mechanical thrombectomy devices and Radial access devices. In addition to these primary platforms, Surmodics’ device manufacturing operations include Specialty catheters.In the second quarter, Surmodics’ R&D expenses were 27.6% of total revenues. Medical Device R&D and other revenues increased 1.4% in the fiscal second quarter compared with the prior-year quarter, driven by increased volume of performance coating services.Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. The company announced the completion of limited market evaluation and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP (Low Profile) Thrombectomy System during the fiscal second quarter.In January, Surmodics announced the successful early clinical use of the Pounce LP Thrombectomy System. Strong Q2 Results: Surmodics registered a solid uptick in the overall top and bottom lines in the second quarter. Product sales growth in the Medical Device segment was driven primarily by the fulfillment of the initial stocking order for the SurVeil DCB from Abbott and continued sales growth from the Pounce thrombectomy device platform.DownsidesRegulatory Headwinds: Surmodics’ facilities and procedures are subject to periodic inspections by the FDA to determine compliance with the latter’s requirements. On account of non-compliance with applicable laws or regulations, the FDA could ban such medical devices. Any adverse regulatory action can potentially hurt Surmodics' business practices and operations.Reliance on Third Parties: A principal element of Surmodics’ business strategy is to enter into licensing arrangements with medical devices and other companies that manufacture products incorporating its technologies. The company’s revenues from such arrangements depend upon its ability or its licensees’ ability to successfully develop, obtain regulatory approval for manufacture (if applicable), and market and sell products incorporating Surmodics’ technologies. Any failure to meet these requirements could have an adverse effect on its business.Estimate TrendSurmodics is witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for its loss per share has narrowed from 90 cents to 72 cents.The consensus estimate for the company’s third-quarter fiscal revenues is pegged at $30.3 million, suggesting a 42.2% decline from the year-ago reported number. Loss for the period is estimated to widen 157.7% year over year to 30 cents per share.Surmodics, Inc. Price Surmodics, Inc. price | Surmodics, Inc. QuoteKey PicksSome better-ranked stocks in the broader medical space are DaVita Inc. (DVA Quick QuoteDVA - Free Report) , Align Technology (ALGN Quick QuoteALGN - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) .DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. DaVita’s shares have risen 33.4% compared with the industry’s 11.2% growth year to date.Medpace, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%.Medpace’s shares have risen 28.3% year to date compared with the industry’s 4.9% growth.Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one quarter, delivering an average surprise of 5.9%.ALGN’s shares have declined 0.9% year to date against the industry’s 2.8% growth. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Surmodics, Inc. (SRDX Quick QuoteSRDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter performance and consistent efforts to boost research and development (R&D) are expected to contribute further. Yet, concerns regarding regulatory headwinds and reliance on third parties persist.So far this year, this current Zacks Rank #3 (Hold) company has declined 4.8% against the industry’s 4.2% rise and the S&P 500’s 11.6% growth.The renowned medical device and in-vitro diagnostics technology provider has a market capitalization of $493.68 million. Surmodics projects 97.2% growth for fiscal 2025 and expects to maintain its strong performance. SRDX’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average earnings surprise being 165.93%. Image Source: Zacks Investment ResearchLet’s delve deeper.Consistent Efforts to Boost R&D: Surmodics’ solid efforts to improve its R&D stature have been a key growth driver, which raises our optimism. The company’s pipeline of vascular intervention medical device products under development and recently commercialized include primary platforms like DCBs, Mechanical thrombectomy devices and Radial access devices. In addition to these primary platforms, Surmodics’ device manufacturing operations include Specialty catheters.In the second quarter, Surmodics’ R&D expenses were 27.6% of total revenues. Medical Device R&D and other revenues increased 1.4% in the fiscal second quarter compared with the prior-year quarter, driven by increased volume of performance coating services.Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. The company announced the completion of limited market evaluation and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP (Low Profile) Thrombectomy System during the fiscal second quarter.In January, Surmodics announced the successful early clinical use of the Pounce LP Thrombectomy System. Strong Q2 Results: Surmodics registered a solid uptick in the overall top and bottom lines in the second quarter. Product sales growth in the Medical Device segment was driven primarily by the fulfillment of the initial stocking order for the SurVeil DCB from Abbott and continued sales growth from the Pounce thrombectomy device platform.DownsidesRegulatory Headwinds: Surmodics’ facilities and procedures are subject to periodic inspections by the FDA to determine compliance with the latter’s requirements. On account of non-compliance with applicable laws or regulations, the FDA could ban such medical devices. Any adverse regulatory action can potentially hurt Surmodics' business practices and operations.Reliance on Third Parties: A principal element of Surmodics’ business strategy is to enter into licensing arrangements with medical devices and other companies that manufacture products incorporating its technologies. The company’s revenues from such arrangements depend upon its ability or its licensees’ ability to successfully develop, obtain regulatory approval for manufacture (if applicable), and market and sell products incorporating Surmodics’ technologies. Any failure to meet these requirements could have an adverse effect on its business.Estimate TrendSurmodics is witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for its loss per share has narrowed from 90 cents to 72 cents.The consensus estimate for the company’s third-quarter fiscal revenues is pegged at $30.3 million, suggesting a 42.2% decline from the year-ago reported number. Loss for the period is estimated to widen 157.7% year over year to 30 cents per share.Surmodics, Inc. Price Surmodics, Inc. price | Surmodics, Inc. QuoteKey PicksSome better-ranked stocks in the broader medical space are DaVita Inc. (DVA Quick QuoteDVA - Free Report) , Align Technology (ALGN Quick QuoteALGN - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) .DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. DaVita’s shares have risen 33.4% compared with the industry’s 11.2% growth year to date.Medpace, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%.Medpace’s shares have risen 28.3% year to date compared with the industry’s 4.9% growth.Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one quarter, delivering an average surprise of 5.9%.ALGN’s shares have declined 0.9% year to date against the industry’s 2.8% growth. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
05/16 12:45 EST - zacks.com
Align Technology (ALGN) Gains From Innovation, Global Expansion
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
Align Technology (ALGN) Gains From Innovation, Global Expansion
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
05/15 11:51 EST - zacks.com
Here's Why You Should Buy Align Technology (ALGN) Stock Now
Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.
05/15 10:45 EST - zacks.com
3 Solid Buys From MedTech Following 2024 Guidance Raise
Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
3 Solid Buys From MedTech Following 2024 Guidance Raise
Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
05/13 13:53 EST - businesswire.com
Align Technology to Speak at Upcoming Financial Conferences
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align Te.
Align Technology to Speak at Upcoming Financial Conferences
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financial conferences. The presentations, as noted below, will be webcast live via the Investor Relations section of Align Te.
05/08 11:13 EST - 247wallst.com
Is Align Technology Stock A Buy?
Align Technology (NASDAQ: ALGN), most notably the makers of Invisalign aligners specializes in orthodontic devices and restorative treatment has been through a whirlwind the past 2 years, with its stock price dropping 60% since its high in September 2021.
Is Align Technology Stock A Buy?
Align Technology (NASDAQ: ALGN), most notably the makers of Invisalign aligners specializes in orthodontic devices and restorative treatment has been through a whirlwind the past 2 years, with its stock price dropping 60% since its high in September 2021.
05/07 11:52 EST - seekingalpha.com
Align Technology: International Strength To Continue Driving Growth Acceleration
Align Technology manufactures 3D digital scanners and clear aligners for teeth straightening in orthodontics. ALGN's stock has seen significant volatility but has rebounded 7% YTD, with a 1-year price target of $313 per share. ALGN's international growth and strong global presence are key catalysts for driving attractive risk-reward, with a growing market for clear aligners.
Align Technology: International Strength To Continue Driving Growth Acceleration
Align Technology manufactures 3D digital scanners and clear aligners for teeth straightening in orthodontics. ALGN's stock has seen significant volatility but has rebounded 7% YTD, with a 1-year price target of $313 per share. ALGN's international growth and strong global presence are key catalysts for driving attractive risk-reward, with a growing market for clear aligners.
05/06 10:46 EST - zacks.com
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.
04/29 17:07 EST - investorplace.com
Cutting Edge Picks: 3 Med Tech Stocks With Room to Run
Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies right now) seek to expand in some pretty massive markets.
Cutting Edge Picks: 3 Med Tech Stocks With Room to Run
Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies right now) seek to expand in some pretty massive markets.
04/26 08:30 EST - businesswire.com
Align Technology Announces $150 Million Open Market Repurchase
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $150 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program that was approved by.
Align Technology Announces $150 Million Open Market Repurchase
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $150 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program that was approved by.
04/25 14:46 EST - zacks.com
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
04/24 20:16 EST - seekingalpha.com
Align Technology, Inc. (ALGN) Q1 2024 Earnings Call Transcript
Align Technology, Inc. (ALGN) Q1 2024 Earnings Call Transcript
Align Technology, Inc. (ALGN) Q1 2024 Earnings Call Transcript
Align Technology, Inc. (ALGN) Q1 2024 Earnings Call Transcript